[
  {
    "ts": null,
    "headline": "Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions",
    "summary": "Amgen (NasdaqGS:AMGN) ended its eczema drug partnership with Kyowa Kirin involving the experimental therapy rocatinlimab. The company also received an FDA request to withdraw Tavneos, a treatment for a rare blood vessel disease, due to concerns about clinical trial data. For you as an investor, these updates sit at the core of what drives a large biopharma story: the pipeline and the product roster. Amgen focuses on therapies in areas such as inflammation and rare diseases, where regulatory...",
    "url": "https://finnhub.io/api/news?id=2a55d4ef889723385ef8d8a4f2d3269090b9f6f003ebc0ae1c8e9b9f6c69e44e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770333155,
      "headline": "Amgen Refocuses Portfolio As Eczema Exit And Tavneos Review Raise Questions",
      "id": 138369834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NasdaqGS:AMGN) ended its eczema drug partnership with Kyowa Kirin involving the experimental therapy rocatinlimab. The company also received an FDA request to withdraw Tavneos, a treatment for a rare blood vessel disease, due to concerns about clinical trial data. For you as an investor, these updates sit at the core of what drives a large biopharma story: the pipeline and the product roster. Amgen focuses on therapies in areas such as inflammation and rare diseases, where regulatory...",
      "url": "https://finnhub.io/api/news?id=2a55d4ef889723385ef8d8a4f2d3269090b9f6f003ebc0ae1c8e9b9f6c69e44e"
    }
  },
  {
    "ts": null,
    "headline": "RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 4, RBC Capital raised its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $360 from $335. The firm also kept an Outperform rating and pointed to a strong fourth quarter on both revenue and earnings. According to the […]",
    "url": "https://finnhub.io/api/news?id=e207d5bfed43d81468c7d347fdd535379dc9ee74f971343449ad3516df441272",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770319422,
      "headline": "RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum",
      "id": 138367557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. On February 4, RBC Capital raised its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $360 from $335. The firm also kept an Outperform rating and pointed to a strong fourth quarter on both revenue and earnings. According to the […]",
      "url": "https://finnhub.io/api/news?id=e207d5bfed43d81468c7d347fdd535379dc9ee74f971343449ad3516df441272"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?",
    "summary": "Wegovy might be getting more competition soon.",
    "url": "https://finnhub.io/api/news?id=ddb4420de1469effb8044cbdf69cda27f31dabbdda5275e75aec95f4b2eaff17",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770307500,
      "headline": "These 2 Companies Could Soon Join the Weight Loss Market: Are They Buys?",
      "id": 138366160,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wegovy might be getting more competition soon.",
      "url": "https://finnhub.io/api/news?id=ddb4420de1469effb8044cbdf69cda27f31dabbdda5275e75aec95f4b2eaff17"
    }
  },
  {
    "ts": null,
    "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
    "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines.",
    "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305054,
      "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
      "id": 138376237,
      "image": "https://image.cnbcfm.com/api/v1/image/108262460-1770383887859-gettyimages-2259525568-TRUMPRX_LAUNCH.jpeg?v=1770384067&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines. ",
      "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft",
    "summary": "AMGN hits a 52-week high on solid revenue growth and rising institutional interest, standing out against richly valued Apple and Microsoft.",
    "url": "https://finnhub.io/api/news?id=5b8c7bacaf97b90dc0720af6b92f0b69dc0d7247941e0f280b6fdae4bc9462da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770304080,
      "headline": "Zacks Investment Ideas feature highlights: Amgen, Apple and Microsoft",
      "id": 138366004,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "AMGN hits a 52-week high on solid revenue growth and rising institutional interest, standing out against richly valued Apple and Microsoft.",
      "url": "https://finnhub.io/api/news?id=5b8c7bacaf97b90dc0720af6b92f0b69dc0d7247941e0f280b6fdae4bc9462da"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall, Bitcoin Dives Below $70,000; Google AI Spending Stuns",
    "summary": "Google earnings were strong, but AI spending stunned. Bitcoin continues to dive while the stock market is deeply divided.",
    "url": "https://finnhub.io/api/news?id=14b53ee46546759401ae67634d29e62ca51b2811c2d7dbd3a24d649d5354d560",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296942,
      "headline": "Dow Jones Futures Fall, Bitcoin Dives Below $70,000; Google AI Spending Stuns",
      "id": 138363452,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Google earnings were strong, but AI spending stunned. Bitcoin continues to dive while the stock market is deeply divided.",
      "url": "https://finnhub.io/api/news?id=14b53ee46546759401ae67634d29e62ca51b2811c2d7dbd3a24d649d5354d560"
    }
  },
  {
    "ts": null,
    "headline": "Generate, an AI-driven Flagship startup, pitches an IPO",
    "summary": "The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.",
    "url": "https://finnhub.io/api/news?id=d9df4a0402d3eaf18e2d4ab7229973863d2777c35c620ea6097924a6ef002223",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770291120,
      "headline": "Generate, an AI-driven Flagship startup, pitches an IPO",
      "id": 138366162,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is developing a potential competitor to the asthma treatment Tezspire.",
      "url": "https://finnhub.io/api/news?id=d9df4a0402d3eaf18e2d4ab7229973863d2777c35c620ea6097924a6ef002223"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "HEALTH NEWS  The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0801 GMT – Siemens Healthineers has bright growth and margin potential in each of its business divisions, Jefferies analysts write in a research note.",
    "url": "https://finnhub.io/api/news?id=c7494fd8f5a90c7fa95dde8662ebd47594306032320ef79762d0b203ed759fd6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770289980,
      "headline": "Health Care Roundup: Market Talk",
      "id": 138363582,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "HEALTH NEWS  The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0801 GMT – Siemens Healthineers has bright growth and margin potential in each of its business divisions, Jefferies analysts write in a research note.",
      "url": "https://finnhub.io/api/news?id=c7494fd8f5a90c7fa95dde8662ebd47594306032320ef79762d0b203ed759fd6"
    }
  },
  {
    "ts": null,
    "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
    "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
    "url": "https://finnhub.io/api/news?id=b683f4b27861a66f1c4a2d2a0a3bab6fe2c5b2d1713ad562a42a731cc6e10ff8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770282000,
      "headline": "BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration",
      "id": 138362075,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.",
      "url": "https://finnhub.io/api/news?id=b683f4b27861a66f1c4a2d2a0a3bab6fe2c5b2d1713ad562a42a731cc6e10ff8"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market News for Feb 5, 2026",
    "summary": "U.S. stock markets closed mixed on Wednesday as sector rotation by market participants continued.",
    "url": "https://finnhub.io/api/news?id=02d8e9571952ba6d5601df747bdd6db8d8495d936df0c316c6efb8dabf1b7d16",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770280800,
      "headline": "Stock Market News for Feb 5, 2026",
      "id": 138362680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "U.S. stock markets closed mixed on Wednesday as sector rotation by market participants continued.",
      "url": "https://finnhub.io/api/news?id=02d8e9571952ba6d5601df747bdd6db8d8495d936df0c316c6efb8dabf1b7d16"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma’s most valuable up-and-coming GLP-1s",
    "summary": "Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.",
    "url": "https://finnhub.io/api/news?id=b57a6a83ce190955e2321ca2fcc05e223961ff17b54907fa35de64fafa5ec66f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770278400,
      "headline": "Big Pharma’s most valuable up-and-coming GLP-1s",
      "id": 138363533,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Late-stage GLP-1 candidates from Eli Lilly, Novo Nordisk and Amgen have a combined net present value of $68 billion.",
      "url": "https://finnhub.io/api/news?id=b57a6a83ce190955e2321ca2fcc05e223961ff17b54907fa35de64fafa5ec66f"
    }
  },
  {
    "ts": null,
    "headline": "Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains",
    "summary": "What Does Amgen's Recent Share Price Action Mean For Its Valuation? Amgen's share price can tell you a lot about what the market thinks it is worth, but the real question is whether that price still lines up with the underlying value of the business. In the last week Amgen returned 6.8%, over the past month 10.9%, year to date 11.8%, over the last year 27.0%, over three years 67.9% and over five years 81.0%. Taken together, these figures give investors a useful snapshot of how sentiment...",
    "url": "https://finnhub.io/api/news?id=b5312cdef91f30e7d42b1bba33d240aa2d2eca28359d292be84745300b510f39",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770268531,
      "headline": "Is It Time To Reassess Amgen (AMGN) After Strong Recent Share Price Gains",
      "id": 138361047,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "What Does Amgen's Recent Share Price Action Mean For Its Valuation? Amgen's share price can tell you a lot about what the market thinks it is worth, but the real question is whether that price still lines up with the underlying value of the business. In the last week Amgen returned 6.8%, over the past month 10.9%, year to date 11.8%, over the last year 27.0%, over three years 67.9% and over five years 81.0%. Taken together, these figures give investors a useful snapshot of how sentiment...",
      "url": "https://finnhub.io/api/news?id=b5312cdef91f30e7d42b1bba33d240aa2d2eca28359d292be84745300b510f39"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures Fall; Google Beats Views, Huge AI Spending Stuns",
    "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
    "url": "https://finnhub.io/api/news?id=90acd7f61c737a1403d80c433737b5483f9b9902f2e097ee23b8d588ebbdc191",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770263614,
      "headline": "Dow Jones Futures Fall; Google Beats Views, Huge AI Spending Stuns",
      "id": 138360472,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
      "url": "https://finnhub.io/api/news?id=90acd7f61c737a1403d80c433737b5483f9b9902f2e097ee23b8d588ebbdc191"
    }
  },
  {
    "ts": null,
    "headline": "CNBC Daily Open: Alphabet could more than double its capex in 2026, unsettling investors",
    "summary": "Alphabet expects capital expenditure for 2026 to come in between $175 billion and $185 billion — at the higher end, capex will more than double from last year.",
    "url": "https://finnhub.io/api/news?id=cf48523a641d5a9debf022db979e653672b95b46182683920a801ce722c8d78d",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770258601,
      "headline": "CNBC Daily Open: Alphabet could more than double its capex in 2026, unsettling investors",
      "id": 138365464,
      "image": "https://image.cnbcfm.com/api/v1/image/108261645-1770242575711-gettyimages-2259951688-_73a9042_xrkcxizk.jpeg?v=1770242732&w=1920&h=1080",
      "related": "AMGN",
      "source": "CNBC",
      "summary": "Alphabet expects capital expenditure for 2026 to come in between $175 billion and $185 billion — at the higher end, capex will more than double from last year.",
      "url": "https://finnhub.io/api/news?id=cf48523a641d5a9debf022db979e653672b95b46182683920a801ce722c8d78d"
    }
  },
  {
    "ts": null,
    "headline": "Dow Jones Futures: Google Beats Views, Huge AI Spending Stuns",
    "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
    "url": "https://finnhub.io/api/news?id=2bcb73da43d86c6d77106bf323b02f5036ddcc85d94a425b5da95304fc5fd897",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770255599,
      "headline": "Dow Jones Futures: Google Beats Views, Huge AI Spending Stuns",
      "id": 138359998,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The rotation out of techs continued in a divided stock market, but Eli Lilly jumped. Google rose late on earnings and huge capital spending plans.",
      "url": "https://finnhub.io/api/news?id=2bcb73da43d86c6d77106bf323b02f5036ddcc85d94a425b5da95304fc5fd897"
    }
  }
]